Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances DOI Creative Commons

Liangtao Zhao,

Haolan Tang,

Zhangjun Cheng

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(12), P. 1724 - 1724

Published: Dec. 20, 2024

Liver fibrosis is a progressive scarring process primarily caused by chronic inflammation and injury, often closely associated with viral hepatitis, alcoholic liver disease, metabolic dysfunction-associated steatotic disease (MASLD), drug-induced autoimmune (AILD). Currently, there are very few clinical antifibrotic drugs available, effective targeted therapy lacking. Recently, emerging immunomodulators have shown promising results in animal studies, some entered research phases. This review aims to systematically the molecular mechanisms underlying fibrosis, focusing on advancements drug treatments for hepatic fibrosis. Furthermore, since progression or endpoint of many diseases, it crucial address etiological treatment secondary prevention We will also pharmacological available common hepatitis leading

Language: Английский

Morin, a Polypharmacological Marvel: Unveiling its versatility and recent advances in bioavailability enhancement DOI
Vani Vijay, Madan Kumar Perumal

Food Bioscience, Journal Year: 2025, Volume and Issue: unknown, P. 106104 - 106104

Published: Feb. 1, 2025

Language: Английский

Citations

1
Morin attenuates high-fat diet induced inflammation and enhances the Akkermansiaceae richness in the gut of C57BL/6J mice DOI

V. Prashanth,

Arun Kumar Devarajan, Madan Kumar Perumal

et al.

Food Bioscience, Journal Year: 2025, Volume and Issue: unknown, P. 106153 - 106153

Published: Feb. 1, 2025

Language: Английский

Citations

1
Morin/hydroxypropyl-β-cyclodextrin inclusion complex showed higher in vivo oral bioavailability and inhibition on LX-2 cell growth DOI
Vani Vijay, A. Panneerselvam,

J.R. Manjunatha

et al.

Food Bioscience, Journal Year: 2024, Volume and Issue: 61, P. 104897 - 104897

Published: Aug. 8, 2024

Language: Английский

Citations

3
Pharmacotherapy of Liver Fibrosis and Hepatitis: Recent Advances DOI Creative Commons

Liangtao Zhao,

Haolan Tang,

Zhangjun Cheng

et al.

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(12), P. 1724 - 1724

Published: Dec. 20, 2024

Liver fibrosis is a progressive scarring process primarily caused by chronic inflammation and injury, often closely associated with viral hepatitis, alcoholic liver disease, metabolic dysfunction-associated steatotic disease (MASLD), drug-induced autoimmune (AILD). Currently, there are very few clinical antifibrotic drugs available, effective targeted therapy lacking. Recently, emerging immunomodulators have shown promising results in animal studies, some entered research phases. This review aims to systematically the molecular mechanisms underlying fibrosis, focusing on advancements drug treatments for hepatic fibrosis. Furthermore, since progression or endpoint of many diseases, it crucial address etiological treatment secondary prevention We will also pharmacological available common hepatitis leading

Language: Английский

Citations

0